The Indianapolis-based Indiana Biosciences Research Institute has announced grants totaling $100 million from the Lilly Endowment and the Eli Lilly and Company Foundation in support of its efforts to address metabolic disease and poor nutrition.
IBRI is the lead tenant in Indianapolis's emerging 16 Tech community, a public-private initiative aimed at attracting the best and brightest life sciences researchers to collaborate, innovate, and commercialize new ideas across a spectrum of industries. A portion of the endowment's $80 million grant, the second-largest it has ever awarded, is subject to a dollar-for-dollar match, including $20 million contributed by the Lilly company foundation, leaving the $15 million balance of the grant still to be matched. With the funding, IBRI now has achieved almost half its three-year fundraising target of approximately $350 million.
"This is a monumental achievement for the Indiana Biosciences Research Institute and for the global life sciences research community," said IBRI president and CEO David Broecker. "We are grateful for the support of Lilly Endowment and the Eli Lilly and Company Foundation, as well as our other partners, and believe these contributions underscore the significance of our vision to build a world class research institute that will serve as a catalyst for accelerating research and innovation."